Dihydrotestosterone (DHT)

Catalog No.S4757 Synonyms: androstanolone, stanolone, 5α-DHT

For research use only.

Dihydrotestosterone (DHT, androstanolone, stanolone, 5α-DHT) is an endogenous androgen sex steroid and hormone and a potent agonist of the androgen receptor with 2-3-fold greater androgen receptor affinity than testosterone and 10-fold higher potency of inducing androgen receptor signaling.

Dihydrotestosterone (DHT) Chemical Structure

CAS No. 521-18-6

Selleck's Dihydrotestosterone (DHT) has been cited by 17 publications

Purity & Quality Control

Choose Selective Androgen Receptor Inhibitors

Other Androgen Receptor Products

Biological Activity

Description Dihydrotestosterone (DHT, androstanolone, stanolone, 5α-DHT) is an endogenous androgen sex steroid and hormone and a potent agonist of the androgen receptor with 2-3-fold greater androgen receptor affinity than testosterone and 10-fold higher potency of inducing androgen receptor signaling.
Targets
Androgen Receptor [1]
In vitro

In AR-positive bladder cancer UMUC3 and TCC-SUP cells, dihydrotestosterone (DHT) increased the expression of EGFR and ERBB2 both in mRNA and in protein levels. DHT additionally upregulated the levels of phosphorylation of EGFR (pEGFR) and its downstream proteins AKT (pAKT) and ERK1/2 (pERK), induced by EGF treatment, in AR-positive cells[1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CV-1 cell MmjGSpVv[3Srb36gZZN{[Xl? NYHwR4hRSWexbnnzeIlkKGGldHn2bZR6KCiHQ{WwLUBi\2GrboP0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBEXi1zIHPlcIwtKEWFNUC9NE4xODZizszN MkLMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwQTh5MUWzOEc,QTh5MUWzOFww[T5?
MDA-MB-453 cell NFXGRmhHfW6ldHnvckBie3OjeR?= MnzUSIl{eGyjY3Xt[Y51KG:oIGuzTH1FUFRiZoLvcUBpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hVUSDLV3CMVQ2OyClZXzsd{BjgSC5aH;s[UBk\WyuIILlZ4VxfG:{IHLpcoRqdmdiYYPzZZktKEurPUCuNFAxOiEQvF2= MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzB|NEGxO{c,OTdyM{SxNVc9N2F-
HepG2 cell NX3w[3BsTnWwY4Tpc44h[XO|YYm= MYXBZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKGGwZILv[4VvKHKnY3XweI9zKGW6cILld5Nm\CCrbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[WO2aY\heIlwdixiSVO1NF0xNjBzOEKg{txO M1LLOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUS5PFY3Lz5zN{G0PVg3PjxxYU6=
MDA453 cell MUTGeY5kfGmxbjDhd5NigQ>? NG\lNWRFcXOybHHj[Y1mdnRib3[gX|NJZUSKVDDmdo9uKGi3bXHuJGFTKGmwIF3ERVQ2OyClZXzsd{whU2l;MD6wNFMh|ryP NV:xVWtpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexPFEyPDFpPkG3NVgyOTRzPD;hQi=>
mouse C2C12 cell NYHOTHRbTnWwY4Tpc44h[XO|YYm= NVfxdYIySWexbnnzeEBi[3Srdnn0fUBifCC{YYSgRXIhfHKjboPm[YN1\WRiaX6gcY92e2ViQ{LDNVIh[2WubIOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiC2cnHud4FkfGm4YYTpc44h[XO|YYmsJGVEPTB;MD6wNlgh|ryP M3vmR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUixNVQyLz5zN{G4NVE1OTxxYU6=
monkey COS7 cell M3f5[GZ2dmO2aX;uJIF{e2G7 Mk[0Rolv\GmwZzDh[oZqdmm2eTD0c{BpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hdW:wa3X5JGNQWzdiY3XscJMh[nlid3jvcIUh[2WubDDibY5lcW6pIHHzd4F6NCCNaU2wMlAxODJizszN MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR2MkmxNkc,OTh2NEK5NVI9N2F-
CHO cell MlrpSpVv[3Srb36gZZN{[Xl? MWjB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGTHVlUh\XiycnXzd4VlKGmwIFPIU{Bk\WyuczDifUBtfWOrZnXyZZNmKGG|c3H5MEBGSzVyPUSuOFkh|ryP NUGzSZN{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizNFczQTRpPkG4N|A4Ojl2PD;hQi=>
COS7 cell NIXTXpVHfW6ldHnvckBie3OjeR?= NXfQToRkSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBidmS{b3flckBz\WOncITvdkBYPzRzQzDteZRidnRiZYjwdoV{e2WmIHnuJGNQWzdiY3XscJMh[XO|ZYPz[YQh[XNibIXjbYZmemG|ZTDhZ5Rqfmm2eTDh[pRmeiB{NDDodpMh[nlicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OD1yLkCxNkDPxE1? M4ribVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEm0Nlc6Lz5{MkC5OFI4QTxxYU6=
COS7 cell NX7qfY46TnWwY4Tpc44h[XO|YYm= MWXB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IGS4O|dCKG23dHHueEBmgHC{ZYPz[YQhcW5iQ1;TO{Bk\WyuczDhd5Nme3OnZDDhd{BtfWOrZnXyZZNmKGGldHn2bZR6KGGodHXyJFI1KGi{czDifUBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvODF3IN88US=> NVXmWXFkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwPVQzPzlpPkKyNFk1Ojd7PD;hQi=>
COS7 cell MUHGeY5kfGmxbjDhd5NigQ>? NHLuWZhC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJIFv\HKxZ3XuJJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCFT2O3JINmdGy|IHHzd4V{e2WmIHHzJIx2[2moZYLhd4Uh[WO2aY\peJkh[W[2ZYKgNlQhcHK|IHL5JJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NE4xODZ{IN88US=> NELQSoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC5OFI4QSd-MkKwPVQzPzl:L3G+
LNCaP-hr cell M3LYdWZ2dmO2aX;uJIF{e2G7 NHjp[Ik{KGSjeYO= NFO5UHlC\2:waYP0JIFkfGm4aYT5JIF1KEGwZILv[4VvKHKnY3XweI9zKFR6N{fBJI12fGGwdDDpckBpfW2jbjDMUmNiWC2qcjDj[YxteyCjc4Pld5Nm\CCjczDwdo9{fGG2ZTDzdIVkcW[rYzDhcpRq\2WwIIPlZ5JmfGmxbjDt[YF{fXKnZDDh[pRmeiB|IHThfZMh[nliZX76fY1mNWmvbYXuc4F{e2G7LDDFR|UxRTBwMEG1JO69VQ>? M4\2NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MUm5OFc4Lz5{M{G5PVQ4PzxxYU6=
LNCaP-hr cell NFP5fIlHfW6ldHnvckBie3OjeR?= NE[zfoY{KGSjeYO= M2X4cWFod26rc4SgZYN1cX[rdImgZZQhf2muZDD0fZBmKEGwZILv[4VvKHKnY3XweI9zKGmwIHj1cYFvKEyQQ3HQMYhzKGOnbHzzJIF{e2W|c3XkJIF{KHC{b4P0ZZRmKHOyZXPp[olkKGGwdHnn[Y4he2WlcnX0bY9vKG2nYYP1doVlKGGodHXyJFMh\GG7czDifUBmdnq7bXWtbY1ufW6xYYPzZZktKEWFNUC9NE4xODZ{IN88US=> M{DUbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MUm5OFc4Lz5{M{G5PVQ4PzxxYU6=
HEK293 cell NVywWZdMTnWwY4Tpc44h[XO|YYm= Ml2xRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NF0xNjF6IH7N MlvoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|MEW2PFgoRjJ3M{C1Olg5RC:jPh?=
COS NGHUSJlHfW6ldHnvckBie3OjeR?= MXrCbY5lcW6pIHHm[olvcXS7IHHnZYlve3RiQX7kdo9o\W5icnXj[ZB1d3JiZYjwdoV{e2WmIFPPV{Bk\WyuczygT4khRSByLkCwNkDPxE1w NIDMRY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi97OEexOVM1Lz57OEexOVM1RC:jPh?=
COS-1 MmL3SpVv[3Srb36gZZN{[Xl? NXrlb3FHSmmwZHnu[{Bi\m[rbnn0fUBnd3JiaIXtZY4hSW6mcn;n[Y4hemWlZYD0c5Ih\XiycnXzd4VlKGmwIFPPV{0yKGOnbHzzMEBMcSB;IECuNFA{KM7:TT6= Mk\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwQTl{NUeyOUc,QTl{NUeyOVww[T5?
CV-1 MkDPSpVv[3Srb36gZZN{[Xl? NWjHcIh2SWexbnnzeEBi[3Srdnn0fUBi\2GrboP0JGh2dWGwIFHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBEXi1zIHPlcIx{NCCHQ{WwJF0hOC5yMEWg{txONg>? NYTwRlQyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOUmyOVczPSd-OUmyOVczPTxxYU6=
COS M4H1[GZ2dmO2aX;uJIF{e2G7 MnTsTY4hfmm2cn:gZolv\GmwZzDh[oZqdmm2eTDheEBpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjD0doFve2[nY4Tl[EBqdnSxIFPPV{Bk\Wyucz6sJGlEPTBiPTCwMlAxPCEQvF2u MoDyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB{M{C2NlgoRjFyMkOwOlI5RC:jPh?=
CV-1 Mmr6SpVv[3Srb36gZZN{[Xl? NVjBUoFZUW5idnn0do8h[WexbnnzeIlkKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gZY5lem:pZX6gdoVk\XC2b4KgeZNqdmdiY3;0doFve2[nY4Tpc44h[XO|YYmgbY4hS1ZvMTDj[Yxtey5uIFXDOVAhRSByLkCwOkDPxE1w MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODJ|ME[yPEc,OTB{M{C2Nlg9N2F-
CV-1 M2DkO2Z2dmO2aX;uJIF{e2G7 MnnkRYdwdmm|dDDhZ5Rqfmm2eTD0c{B1cGViaIXtZY4h[W6mcn;n[Y4hemWlZYD0c5IhMGiDUjmgbY4hS1ZvMTDj[YxteyxiRVO1NEA:KDBwMEC2JO69VS5? MlzuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB|NEC2NlQoRjFyM{SwOlI1RC:jPh?=
CV1 NXzEXGpXTnWwY4Tpc44h[XO|YYm= NGfrVIxC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJIFv\HKxZ3XuJJJm[2WydH;yJIlvKEOYMTDj[YxteyCvZXHzeZJm\CCjczDzeIlufWyjdHnvckBw\iCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[WO2aY\peJkh[nliY3;0doFve2[nY4Tpc44h[XO|YYmsJGVEPTBiPTCwMlAxPTFizszNMi=> NWjHcoY6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUewN|QyOTdpPkG3NFM1OTF5PD;hQi=>
CV1 NWf1b3JYTnWwY4Tpc44h[XO|YYm= MVHCbY5lcW6pIHHm[olvcXS7IITvJIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBEXjFiY3XscJMtKEurIE2gNE4xODB{IN88UU4> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzJ3N{izPEc,OTd{NUe4N|g9N2F-
CV1 NGnIeXFHfW6ldHnvckBie3OjeR?= MniyRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hS1ZzIHPlcIx{NCCHQ{WwJF0hOC5yMEWxJO69VS5? M4\POFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MkW3PFM5Lz5zN{K1O|g{QDxxYU6=
MDA-MB-453 Ml71SpVv[3Srb36gZZN{[Xl? MkXxSIl{eGyjY3Xt[Y51KG:oIGuzTH1FUFRiZoLvcUBpfW2jbjDBVkBmgHC{ZYPz[YQhcW5iTVTBMW1DNTR3MzDj[YxteyxiS3mgQUAxNjByMEOg{txONg>? NHHLNHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{SzPVEyOid-MUe0N|kyOTJ:L3G+
CV1 MWnGeY5kfGmxbjDhd5NigQ>? MofmRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hS1ZzIHPlcIx{KGK7IITyZY5{[3KrcITpc45idCCjY4TpeoF1cW:wIHHzd4F6NCCHQ{WwJF0hOC5yMEW3JO69VS5? MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzR|OUGxNkc,OTd2M{mxNVI9N2F-
CV1 MXjGeY5kfGmxbjDhd5NigQ>? MV;B[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBEXjFiY3XscJMh[nlidILhcpNkemmydHnvcoFtKGGldHn2ZZRqd25iYYPzZZktKEWFNUCgQUAxNjByNUeg{txONg>? MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzdyM{mzPEc,OTd5MEO5N|g9N2F-
MDA-MB-453 NWHSNnZNTnWwY4Tpc44h[XO|YYm= MnTZSIl{eGyjY3Xt[Y51KG:oIGuzTH1FUFRiZoLvcUBpfW2jbjDBcoRzd2enbjDy[YNmeHSxcjDpckBpfW2jbjDNSGEuVUJvNEWzJINmdGy|LDDLbUA:KDBwMECwPUDPxE1w NWLIcZpWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0NFA1QTlpPkG4OFAxPDl7PD;hQi=>
CV1 MnrZSpVv[3Srb36gZZN{[Xl? NGfhS3JC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJIFv\HKxZ3XuJJJm[2WydH;yJIlvKEOYMTDj[YxteyCkeTD0doFve2O{aYD0bY9v[WxiYXP0bZZifGmxbjDhd5NigSxiRVO1NEA:KDBwMEC1O{DPxE1w M3HPNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NECwOFk6Lz5zOESwNFQ6QTxxYU6=
Saos2 NHTRNJhHfW6ldHnvckBie3OjeR?= MWDBZ5Rqfmm2eTDheEBidmS{b3flckBz\WOncITvdkBqdiCqdX3hckBU[W:|MjDj[YxteyCjc4Pld5Nm\CCjczDJUFYhemWycnXzd4lwdixiSVO1NEA:KDBwMECwNFUh|ryPLh?= M3znV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NESyPVEzLz5zOES0NlkyOjxxYU6=
CV1 NF7aPXlHfW6ldHnvckBie3OjeR?= NG\wXGxC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJIFv\HKxZ3XuJJJm[2WydH;yJIFnemmlYX6g[5Jm\W5ibX;ub4V6KEOYMTDj[YxteyCkeTDjc5Rz[W6|ZnXjeIlwdiCjc4PhfUwhTUN3MDC9JFAvODB3MTFOwG0v NYrrN5hXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0OFI6OTJpPkG4OFQzQTF{PD;hQi=>
MDA-kb2 NVLMdllmTnWwY4Tpc44h[XO|YYm= NEixSlVC\2:waYP0JIFkfGm4aYT5JIF1KGGwZILv[4VvKHKnY3XweI9zKGmwIHj1cYFvKE2GQT3rZlIh[2WubIOgZZN{\XO|ZXSgZZMhe3SrbYXsZZRqd25ib3[gcJVkcW[ncnHz[UBi[3Srdnn0fUBjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGVEOTVyIE2gNE4xODB3IN88UU4> MneyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3OUKyOFUoRjF7NUmyNlQ2RC:jPh?=
MDA-kb2 MnTISpVv[3Srb36gZZN{[Xl? NHzRbZNC\2:waYP0JIFkfGm4aYT5JIF1KGeudXPvZ49zfGmlb3nkJJJm[2WydH;yJIlvKGi3bXHuJG1FSS2tYkKgZ4VtdHNiYYPz[ZN{\WRiYYOgd5RqdXWuYYTpc44hd2ZibIXjbYZmemG|ZTDhZ5Rqfmm2eTDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDNVUxKD1iMD6wNFA2KM7:TT6= M3vQTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUmyNlQ2Lz5zOUW5NlI1PTxxYU6=
MDA-MB-453 NIHNOGpHfW6ldHnvckBie3OjeR?= MnXwSIl{eGyjY3Xt[Y51KG:oIGuzTH1u\XSqeXz0dolmdm:ub37lJIZzd21iYX7kdo9o\W5icnXj[ZB1d3JiaX6gbJVu[W5iTVTBMW1DNTR3MzDj[YxteyxiSVO1NEA:KDBwMECxJO69VS5? MmnHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl4ME[4O|AoRjF7NkC2PFcxRC:jPh?=
MDA-MB-453 MmnPSpVv[3Srb36gZZN{[Xl? NWHq[Ws4SWexbnnzeEBi[3Srdnn0fUBifCCjbnTyc4dmdiC{ZXPldJRweiCrbjDoeY1idiCPRFGtUWIuPDV|IHPlcIx{KHS{YX7z[oVkfGWmIIfpeIghVU2WVj3MWWMh[XO|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJG1OXFZvTGTSM5Bzd22xdHXyJIxqdmunZDDMWWMh\2WwZTDifUBtfWOrZnXyZZNmKHS{YX7zZYN1cX[jdHnvckBie3OjeTygSWM2OCB;IECuNFAzKM7:TT6= M3TpUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NkC2PFcxLz5zOU[wOlg4ODxxYU6=
NIH3T3 NHX6NlVHfW6ldHnvckBie3OjeR?= M3rqNGFod26rc4SgZYN1cX[rdImgZZQh[W6mcn;n[Y4hemWlZYD0c5IhVEKGIGS4O|dCKG23dHHueEBqdiCvb4Xz[UBPUUh|VEOgZ4VtdHNidILhcpNq\W62bImgeJJidnOoZXP0[YQhf2m2aDDi[ZRiNWejbHHjeI9{cWSjc3WgdoVxd3K2ZYKg[4Vv\SCjc4Pld5Nm\CCjczDj[YxtfWyjcjD0doFve2[xcn3heIlwdiCkeTDSMXNCXCCjc4PhfUwhTUN3MDC9JFAvODBzMkW5JO69VS5? NX33T3lQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4OVY6OjFpPkG5PFU3QTJzPD;hQi=>
NIH3T3 MXnGeY5kfGmxbjDhd5NigQ>? MVnB[49vcXO2IHHjeIl3cXS7IHH0JIFv\HKxZ3XuJJJm[2WydH;yJIlvKG2xdYPlJG5KUDOWMzDj[YxteyC2cnHud4lmdnSueTD0doFve2[nY4Tl[EB4cXSqIHLleIEu\2GuYXP0c5Nq\GG|ZTDy[ZBwenSncjDn[Y5mKGG|c3Xzd4VlKGG|IHPlcIx2dGG{IITyZY5{\m:{bXH0bY9vKGK7IGKtV2FVKGG|c3H5MEBGSzVyIE2gNE4xODN7OEGg{txONg>? M2fp[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEW2PVIyLz5zOUi1OlkzOTxxYU6=
COS7 MYfGeY5kfGmxbjDhd5NigQ>? MXnB[49vcXO2IHHjeIl3cXS7IHH0JIFv\HKxZ3XuJJJm[2WydH;yJIxq\2GwZDDibY5lcW6pIHTvcYFqdiCneIDy[ZN{\WRiaX6gZYZzcWOjbjDndoVmdiCvb37r[ZkhS0:VNzDj[YxteyClbz30doFve2[nY4Tl[EB4cXSqIFfhcFQuTEKGIHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NEA:KDBwMEKg{txONg>? NUG3XIE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4OlMxQDNpPkG5PFY{ODh|PD;hQi=>
Freestyle293F MU\GeY5kfGmxbjDhd5NigQ>? NGPiW4k{KGi{cx?= M3;kb2Rqe3CuYXPlcYVvfCCxZjDbNVcu[WyyaHGtcYV1cHmuLUPIYU1ucWKxbHXyc45mKG[{b32gbJVu[W5iYX7kdo9o\W5icnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGhGUzJ7MzDk[ZJqfmWmIF\y[YVUfHmuZUK5N2Yh[2WubIOgZYZ1\XJiMzDodpMtKEmFNUCgQUAxNjByMkGg{txONg>? NFnie|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC5OFI4QSd-MkKwPVQzPzl:L3G+
Freestyle293F M{ftNWZ2dmO2aX;uJIF{e2G7 NIX0[3g{KGi{cx?= MYXEbZNxdGGlZX3lcpQhd2ZiW{G3MYFteGijLX3leIh6dC1|SG2tcYljd2yncn;u[UBnem:vIHj1cYFvKGGwZILv[4VvKHKnY3XweI9zKFR6N{fBJI12fGGwdDDlfJBz\XO|ZXSgbY4hUEWNMkmzJIRmemm4ZXSgSpJm\VO2eXzlNlk{TiClZXzsd{Bi\nSncjCzJIhzeyxiSVO1NEA:KDBwMECyOkDPxE1w NXPPeWZURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwPVQzPzlpPkKyNFk1Ojd7PD;hQi=>
HeLa MmX1SpVv[3Srb36gZZN{[Xl? NVnsTZV[XHKjboPhZ5RqfmG2aX;uJI9nKGi3bXHuJIFv\HKxZ3XuJJJm[2WydH;yJJRz[W6|ZnXjeIVlKGmwIHj1cYFvKEinTHGgZ4VtdHNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCDY4Tpeol1gSB;IECuNFA5KM7:TT6= M3vnSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEm3OlEyLz5{Mki5O|YyOTxxYU6=
HeLa M3fmXGZ2dmO2aX;uJIF{e2G7 MkPlVIFzfGmjbDDh[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBJ\UyjIHPlcIx{KGOxLXX4dJJme3OrbnegRXJGKGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCkYYPl[EB1emGwc3HjeIl3[XSrb36gZZN{[XluIFHjeIl3cXS7IE2gNE4xODhizszNMi=> M{DIelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUW3PVQ4Lz5{Mkm1O|k1PzxxYU6=
Freestyle293F NYi1fJZ1TnWwY4Tpc44h[XO|YYm= M{HPeWlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFHu[JJw\2WwIILlZ4VxfG:{IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGZz\WW|dIns[VI6O0ZiY3XscJMtKEmFNUCgQUAxNjByMkGg{txONg>? NUDh[I1QRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxPVk1PzdpPkKzNVk6PDd5PD;hQi=>
Freestyle293F NVPEelJGTnWwY4Tpc44h[XO|YYm= MnKyTY5pcWKrdHnvckBw\iCDbnTyc4dmdiC{ZXPldJRweiCWOEe3RUBufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hTnKnZYP0fYxmOjl|RjDj[YxteyxiSVO1NEA:KDBwMECyOkDPxE1w NF\pVm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G5PVQ4Pyd-MkOxPVk1Pzd:L3G+
COS7 M3fafWZ2dmO2aX;uJIF{e2G7 MXKyJIhzew>? Mo\DSIl{eGyjY3Xt[Y51KG:oIGuzTH0hZTWjbIDoZU1FUFRiZoLvcUBud3W|ZTDhcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hdW:wa3X5JGNQWzdiY3XscJMh[W[2ZYKgNkBpenNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yCjbnHsfZNqeyxiSVO1NEA:KDBwMECxJO69VS5? M2\LVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUK3PFE3Lz5{M{WyO|gyPjxxYU6=
C2C12 NGfOfFZHfW6ldHnvckBie3OjeR?= M4TGOVUh\GG7cx?= M3[1RWFod26rc4SgZYN1cX[rdImgZZQh[W6mcn;n[Y4hemWlZYD0c5Ih\XiycnXzd4VlKGmwIH3veZNmKEN{Q{GyJINmdGy|IHHzd4V{e2WmIHHzJI9{fGWxYnzhd5Qh\GmoZnXy[Y51cWG2aX;uJIFnfGW{IEWg[IF6eyxiRVO1NEA:KDBwMECwNFUh|ryPLh?= M37kSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwNlkxLz5{NEmwNFI6ODxxYU6=
C2C12 Mn34SpVv[3Srb36gZZN{[Xl? NF3rfYRC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJIFv\HKxZ3XuJJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCvb4Xz[UBEOkNzMjDj[YxteyCkeTDhcoRzd2enbj3zdIVkcW[rYzDy[ZNxd26|ZTDlcIVu\W62LXTybZZmdiCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGVEPTBiPTCwMlAxODF|IN88UU4> NEnwNG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyNVk3PCd-MkWxNlE6PjR:L3G+
COS7 NWXPWY5rTnWwY4Tpc44h[XO|YYm= MnTsNlQhcHK| NITxWXpC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJGFTKGW6cILld5Nm\CCrbjDB[pJq[2GwIHfy[YVvKG2xbnvlfUBEV1N5IHPlcIx{KGGodHXyJFI1KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVAhRSByLkCwN{DPxE1w MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR3NEi0PUc,Ojh2NUS4OFk9N2F-
Shionogi NVHPcZlOTnWwY4Tpc44h[XO|YYm= NEXWVGkyOCCyTR?= M1O1Nmlv\HWldHnvckBw\iCycn;sbYZmemG2aX;uJI9nKG2xdYPlJHNpcW:wb3fpJINmdGy|IHH0JFExKHCP NEHwb2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{exNVg2PSd-MUe3NVE5PTV:L3G+
MCF7 M{\LS2Z2dmO2aX;uJIF{e2G7 NWfLSHZmOzBidV2= MmiwNlQhcHK| NWHlSlVtSW62YXfvcol{fCCjY4Tpeol1gSCjdDDBVkBqdiCqdX3hckBOS0Z5IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBCWiCuZY\lcEBifCB|MDD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{KHKnbHH0bZZmKHSxIHPvcpRzd2x? M{LofFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEG0O|UyLz5{MkCxOFc2OTxxYU6=
Assay
Methods Test Index PMID
Western blot Cyclin D1 / Cyclin D2 / Cyclin D3 / Cyclin E2 / Cyclin A1 / AR ; p-CDK2 / CDK2 / CDK4 / CDK6 / CDKN1A / p-RB / RB ; p27 / p-p27 ; AR / PP1 26372468 22139837 26636645
Immunofluorescence FOXO1 / p27 ; AKT(S473) / PKCα(S657) 22139837
In vivo DHT-treated SOD1-G93A mice demonstrate ameliorated muscle atrophy and increased body weight, which is associated with stronger grip-strength. DHT treatment increases the expression of insulin-like growth factor-1 in muscle, which can exert myotrophic as well as neurotrophic effects through retrograde transport. DHT treatment attenuates neuromuscular junction denervation, and axonal and motoneuron loss. DHT-treated SOD1-G93A mice demonstrates improvement in motor behavior as assessed by rota-rod and gait analyses, and an increased lifespan[2].

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: Bladder cancer cells
  • Concentrations: 1 nM
  • Incubation Time: 24 h
  • Method:

    Bladder cancer cells at a density of 50-60% confluence in 24-well plates are co-transfected with 250 ng of MMTV-luc reporter plasmid DNA and 2.5 ng of PRL-TK-luc plasmid DNA. After 6 h of transfection, the medium is replaced with another medium supplemented with charcoal-stripped FBS in the presence or absence of ligands (DHT, HF, or both) for 24 h. Cells were harvested, lysed, and assayed for luciferase activity.

Animal Research:

[2]

  • Animal Models: SOD1-G93A mutant mice with the congenic C57BL/6J background
  • Dosages: 5 mg
  • Administration: silastic implant

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 290.44
Formula

C19H30O2

CAS No. 521-18-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC12CCC(=O)CC1CCC3C2CCC4(C3CCC4O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04989972 Withdrawn Drug: PSIL428|Dietary Supplement: Oyster mushroom Anxiety and Depression Wake Network Inc.|Professor Roger Gibson Section of Psychiatry Faculty of Medical Sciences UWI September 15 2022 Phase 2
NCT05033444 Recruiting Drug: PRV-002|Drug: Placebo Traumatic Brain Injury (TBI) Odyssey Group International Inc.|Avance Clinical Pty Ltd. September 17 2021 Phase 1
NCT05042895 Recruiting Procedure: Group A|Procedure: Group B Infertility Woman''s Health University Hospital Egypt August 20 2021 Not Applicable

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Dihydrotestosterone (DHT) | Dihydrotestosterone (DHT) supplier | purchase Dihydrotestosterone (DHT) | Dihydrotestosterone (DHT) cost | Dihydrotestosterone (DHT) manufacturer | order Dihydrotestosterone (DHT) | Dihydrotestosterone (DHT) distributor